PMID-34644471 – Intranasal Oxytocin in Children with Autism NEJM
Sikich L, Kolevzon A, King BH, McDougle CJ, Sanders KB, Kim SJ, Spanos M, Chandrasekhar T, Trelles MDP, Rockhill CM, Palumbo ML, Witters Cundiff A, Li Q, Lim-Liberty M, Friedman N, Veenstra-VanderWeele J. "Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder," N Engl J Med, 2021;385(16):1462-1473.
Quick Reference
| Property | Value |
|---|---|
| PMID | 34644471 |
| DOI | 10.1056/NEJMoa2103583 |
| Year | 2021 |
| Journal | New England Journal of Medicine |
| Study Type | RCT |
| Evidence Level | I |
| Sample | n=290 children and adolescents (ages 3-17) with autism spectrum disorder |
| Peptide(s) Studied | Oxytocin |
Key Findings
- Largest and most rigorous RCT of intranasal oxytocin for autism spectrum disorder (ASD)
- 290 children/adolescents randomized to intranasal oxytocin or placebo for 24 weeks
- Primary outcome: no significant difference between oxytocin and placebo on the Aberrant Behavior Checklist-Modified Social Withdrawal subscale
- Secondary social functioning outcomes also showed no significant benefit
- Oxytocin was well-tolerated with a safety profile similar to placebo
- Results contradicted earlier smaller, positive studies that had generated significant clinical enthusiasm
- Landmark negative trial that substantially recalibrated expectations for oxytocin in ASD
Study Design
Multicenter, randomized, double-blind, placebo-controlled trial across 7 US academic medical centers. Children and adolescents (ages 3-17) with confirmed ASD received intranasal oxytocin (dose titrated by age: 8-80 IU/day) or matched placebo for 24 weeks. Primary endpoint was change in Aberrant Behavior Checklist-Modified Social Withdrawal subscale. Multiple secondary outcomes included Clinical Global Impression and Social Responsiveness Scale.
Limitations
- Negative trial may reflect true lack of efficacy or may be influenced by dose selection, administration compliance, or heterogeneity of ASD phenotypes
- Intranasal delivery has variable CNS penetration; peripheral oxytocin levels may not reflect central receptor occupancy
- Age range was broad (3-17), potentially mixing developmental stages with different responsiveness
- 24-week duration may be insufficient for social learning-based improvements
Clinical Relevance
This NEJM trial is a critical reference for any practitioner considering oxytocin therapy. Its negative result in a well-powered, rigorously designed study establishes that intranasal oxytocin does not broadly improve social functioning in ASD. This does not rule out benefit in specific ASD subpopulations or for other indications (anxiety, PTSD, bonding), but it substantially weakens the evidence for oxytocin as a general ASD intervention. Practitioners should counsel patients accordingly and not overstate the evidence for social benefits.
Related
#research #RCT #evidence-level-I